In recent years, it has become increasingly clear to researchers that the protein galectin-3 is involved in inflammatory diseases in the brain. A study led by researc...

Early-stage research in the U.K. is set for a bump after a Keytruda windfall, while two startups gain a healthy boost ...

For the past several years, the annual meeting of the American Society of Clinical Oncology has provided a stage for cancer immunotherapy's rapid rise, documenting ma...

Vertex will partner with Kymera Therapeutics in a four-year development deal that hands the Atlas Venture-backed biotech $70 million in cash and equity investment...

Solid Biosciences announced Monday that one of two patients in the "dose-escalation" phase of its Duchenne muscular dystrophy gene therapy trial experienced liver ...

Today is the day your company is finally able to release your brand-new product; however, if your company is a relatively new name to the market, you may find it diff...

After inking an R&D deal almost a year ago to the day, AbbVie and Voyager Therapeutics announced another agreement Friday, expanding their partnership to incl...

Gilead is tapping into a young drugmaker's technology and stores of patient data to find new treatments for diabetic kidney disease and a couple less common kidne...

Roche and PTC Therapeutics' risdiplam helped babies with the most severe form of spinal muscular atrophy achieve important motor milestones and kept them from losi...

Semma Therapeutics hopes to cure Type 1 diabetes by perfecting a process for regenerating insulin-producing beta cells...